Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Greenwich LifeSciences, Inc. - Common stock (NQ:GLSI)

13.32 -0.18 (-1.33%)
Streaming Delayed Price Updated: 12:22 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Greenwich LifeSciences, Inc. - Common stock

< Previous 1 2 3 4 Next >
News headline image
3 Stocks Insiders Are Snapping Up. Do They Know Something We Don’t? ↗
Insider trading is heavily regulated, but it still happens, and it's worth paying attention to big moves from insiders for potential profits. 
Via InvestorPlace
News headline image
Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences to Present at the Benzinga Healthcare Small Cap Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences to Participate in Citi’s 16th Annual Biopharma Virtual Conference
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Set to Join Russell 2000® Index
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2021 ↗
Upgrades For Chatham Lodging Trust (NYSE: 
Via Benzinga
News headline image
Greenwich LifeSciences' Breast Cancer Vaccine Unveils Five Year Data, Confirming to Prevent Metastatic Breast Cancer Recurrence ↗
Greenwich LifeSciences Inc (NASDAQ: GLSI) presented five-year data from Phase 2 breast cancer clinical trial evaluating GP2 immunotherapy in patients who have... 
Via Benzinga
News headline image
Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated
From Greenwich LifeSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers Tilray (NASDAQ:TLRY) shares incre... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Renalytix AI (NASDAQ:RNLX) shares rose 21.41% to $30.62 during Thursday's regular session. Renalytix AI's stock is trading at a volume of 1.0 million... 
Via Benzinga
Topics Artificial Intelligence
News headline image
1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences? ↗
The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now? 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Insider Buys Greenwich LifeSciences Shares ↗
Greenwich LifeSciences Inc (NASDAQ:GLSI) was trading 4.4% higher from the previous closing price. CEO Patel Snehal filed a Form 4 with the SEC on Wednesday, April 14. The... 
Via Benzinga
Topics Regulatory Compliance
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Akumin (NASDAQ:AKU) shares increased by 13.54% to $3.52 during Wednesday's pre-market session. The market value of their outstanding shares is at $247.0... 
Via Benzinga
News headline image
Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Intec Pharma (NASDAQ:NTEC) shares increased by 7.67% to $4.35 during Monday's after-market session. Intec Pharma's trading volume hit 412 shares by close,... 
Via Benzinga
News headline image
55 Biggest Movers From Yesterday ↗
Gainers Celcuity Inc. (NASDAQ: CELC) jumped 29.4% to settle at $27.94. Celcuity shares climbed 51% on Friday after the company announced a worldwide licensing agreement with... 
Via Benzinga
News headline image
Why Greenwich LifeSciences Stock Tanked Today ↗
The drop came despite the clinical-stage biotech announcing good news over the weekend. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers 180 Life Sciences (NASDAQ:ATNF) shares increased by 27.31% to $12.4 during Monday's regular session. Trading volume for 180 Life Sciences's stock is 29.3... 
Via Benzinga
News headline image
42 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 44.8% to $8.05 after the company's 13D filing showed that Modell's Sporting Goods had reported a stake... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Open Lower; Microsoft To Acquire Nuance ↗
Following the market opening Monday, the Dow traded down 0.27% to 33,708.58 while the NASDAQ fell 0.54% to 13,825.03. The S&P also fell, dropping 0.20% to 4,120.48. The U.S.... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Auris Medical Holding (NASDAQ:EARS) stock increased by 21.8% to $5.25 during Monday's pre-market session. The company's market cap stands at $67.5 million... 
Via Benzinga
News headline image
28 Stocks Moving in Monday's Pre-Market Session ↗
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) rose 73.6% to $9.65 in pre-market trading. Modell's Sporting Goods reported a stake of 18.4% in a 13D filing on Friday.... 
Via Benzinga
News headline image
REPEAT/Greenwich LifeSciences Presents Phase IIb Poster, Published April 10th at 2021 AACR Annual Meeting, Showing GP2 Immune Response Peaked at 6 Months, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
From Greenwich LifeSciences, Inc.
Via Business Wire
News headline image
51 Biggest Movers From Friday ↗
Gainers Celcuity Inc. (NASDAQ: CELC) shares climbed 50.9% to close at $21.60 on Friday after the company announced a worldwide licensing agreement with Pfizer to develop and... 
Via Benzinga
News headline image
38 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Celcuity Inc. (NASDAQ: CELC) shares jumped 64.5% to $23.54 after the company announced a worldwide licensing agreement with Pfizer to develop and commercialize... 
Via Benzinga
News headline image
Why Greenwich LifeSciences Stock Is Rising Today ↗
The company reported positive data for its cancer immunotherapy candidate GP2. 
Via The Motley Fool
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.